.jpeg)
2026-04-10 05:57:45
Odevixibat (Bylvay) is the first FDA-approved oral IBAT inhibitor for Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome. By reducing bile acid reabsorption, it lowers serum levels and alleviates liver damage, offering a novel therapy for pediatric and adult patients.
2026-04-10 05:37:39
Futibatinib is a selective FGFR1-4 kinase inhibitor targeting cholangiocarcinoma with FGFR alterations. By blocking oncogenic signaling, it offers a novel treatment option for patients with refractory disease, following genetic testing confirmation.
2026-04-10 05:05:56
Ibrutinib, a BTK inhibitor, targets mantle cell lymphoma, chronic lymphocytic leukemia, and other blood cancers by blocking the B-cell receptor pathway. Monotherapy or combination regimens improve outcomes, while managing risks such as bleeding and infections.
2026-04-10 04:56:03
Axitinib, a targeted therapy, demonstrates significant efficacy in advanced renal cell carcinoma (RCC). Combining with immunotherapy or as monotherapy, it offers innovative first-line and second-line treatment approaches, effectively prolonging survival and improving quality of life while managing potential side effects.
2026-04-09 05:56:04
Trametinib, an oral selective MEK1/2 inhibitor, in combination with dabrafenib revolutionizes treatment for BRAF-mutant melanoma, NSCLC, and rare cancers, offering targeted efficacy and manageable safety profile.
2026-04-09 05:45:58
Pirtobrutinib, an innovative non-covalent BTK inhibitor, provides a treatment option for patients with relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), featuring a unique mechanism and manageable safety profile.
2026-04-09 05:34:17
Provides a comprehensive interpretation of the findings from the POLAR phase II basket trial, published in Nature Medicine in March 2026. It details the efficacy, biomarker analysis, and clinical value of olaparib (a PARP inhibitor) combined with pembrolizumab (an anti-PD-1 immunotherapy) as biomarker-guided maintenance therapy for patients with metastatic pancreatic cancer who achieved disease control after platinum-based chemotherapy, offering cutting-edge clinical reference for the precision treatment of pancreatic cancer.
2026-04-09 05:22:20
This article systematically reviews the basic pharmaceutical properties, anti-tumor mechanism of action, approved indications, standard dosage and administration, pre-infusion preparation, and adverse event management of Sacituzumab Govitecan, providing a professional and comprehensive medication reference for oncology patients and clinical healthcare providers.
2026-04-07 04:45:06
The drug properties and mechanism of action of Fulvestrant (brand name Faslodex), systematically sorts out its indications, standard dosage, dose adjustment rules, adverse reactions and safety precautions for single-agent and combined treatment of breast cancer, providing professional reference for clinical diagnosis and treatment as well as patient medication.
2026-04-07 03:22:33
The clinical medication regimen of Avatrombopag (brand name Doptelet) 20mg specification, details the initial dose, adjustment rules and personalized medication principles for immune thrombocytopenia and chronic liver disease-related thrombocytopenia, to provide professional reference for clinical safe medication.
2026-04-07 02:55:19
This article explains the core pharmacological mechanism of Gilteritinib (brand name Xospata) in the treatment of FLT3-mutated acute myeloid leukemia (AML), and sorts out the relevant impacts of drug discontinuation on disease control and clinical outcomes, to provide professional reference for clinical medication decision-making.
2026-04-03 07:03:54
Avatrombopag (brand name Doptelet) and Hetrombopag are both oral thrombopoietin (TPO) receptor agonists, core treatments for thrombocytopenia. While sharing a homologous mechanism of action, they have clear differences in molecular structure, global indication coverage, clinical application scenarios, and pharmacokinetic profiles. This article explains their key distinctions and clinical selection logic.
